http://jcps.bjmu.edu.cn

• Full Papers • Previous Articles     Next Articles

Safety and Tolerance of Adefovir Dipivoxil in Chinese Healthy Volunteers: A PhaseⅠRandomized and Open-Label Trial

SUN De-qing, NI Mei-yuan, WANG Ben-jie, GUO Rui-chen*   

  1. 1.Department of Pharmacy, the Second Hospital of Shandong University, Jinan 250033, China;
    2.Department of Pharmaceutics, Qilu Hospital of Shandong University, Jinan 250012, China;
    3.Institute of Clinical Pharmacology, Qilu Hospital of Shandong University, Jinan 250012, China
  • Received:2005-01-17 Revised:2005-11-10 Online:2005-12-15 Published:2005-12-15
  • Contact: GUO Rui-chen*

Abstract: Aim To assess the safety and tolerance of adefovir dipivoxil (ADV) in Chinese healthy volunteers. Methods A total of 52 healthy volunteers, 26 males and 26 females, aged from 19 to 26 were enrolled in the study. Forty-two subjects were randomized into 5, 10, 20, 40, and 60 mg dose groups (6-10 subjects in each) matched by sex and weight for single-dose trial. Ten subjects were orally given 10 mg of ADV tablets once daily for 7 d for multiple-dose trial. Physical examination, vital signs examination, electrocardiography, type-B ultrasonography, chest fluoroscopy, routine blood test, routine urine test, coagulation tests, and blood biochemical test were conducted on schedule and statistically evaluated. Results Asthenia frequently occurred in multiple-dose trial, nausea, abdominal pain, and diarrhea occurred in both single- and multiple-dose trials. ALT, bilirubin, CK, and LDH were slightly elevated. All adverse reactions and laboratory abnormalities were mild, and the frequency and severity were not related to doses. Conclusion ADV is safe and well tolerated in Chinese healthy volunteers at dose of 5-60 mg once daily or 10 mg once daily for 7 d. The recommended oral dosage regimen is 10 mg once daily. Attention should be paid to renal and liver functions, CK, AMY and LDH, if we take ADV for a long period of time.

Key words: adefovir dipivoxil, adefovir dipivoxil, safety, safety, tolerance, tolerance, phase I trial, phase I trial

Supporting: